Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
ACADEMIA
Fabricated Data Found in 5 Papers by Ex-NCVC/Osaka Univ. Doctor; 1 Used to Design JANP Study
Osaka University and the National Cerebral and Cardiovascular Center (NCVC) said on August 18 that five papers written by Takashi Nojiri, who was formerly affiliated with both institutions, contained fabricated and falsified data. One of these papers was used as…
To read the full story
Related Article
- MHLW Panel Allows Osaka Univ. Hospital to Continue JANP Study, Requires Report by Year End: Data Scandal
September 15, 2020
- MHLW Panel to Ask Osaka Univ. Hospital to Quickly Report on Scientific Validity of Paper: Fabricated Data Scandal
August 24, 2020
- Shionogi Funding Research to Develop World’s First Drug for Preventing Postoperative Metastasis of Lung Cancer
January 5, 2016
ACADEMIA
- Tavneos Patients Shift to Other Therapies as Japan Weighs Revocation: Investigator
November 4, 2026
- Early Pregnancy DOAC Exposure Not Linked to Higher Birth Defect Risk: Study
October 30, 2026
- First iPS Heart Sheet Patient Recovering Well, Set for Discharge
October 22, 2026
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
- Bosutinib Set to Enter PIII for ALS in Japan in 2027
October 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…